Editorial Material
Medicine, General & Internal
Zhijun Zhou, Min Li
Summary: Targeted therapy is crucial for improving overall survival and reducing side effects in cancer treatment, but each patient responds differently to treatment. The development of cutting-edge technologies, such as next-generation sequencing, has allowed for the identification of more actionable targets. This special issue of BMC Medicine presents a collection of studies on targeted therapies for various cancer types, aiming to bridge the gap between genomic testing and precision medicine and spark innovations in improving the efficacy of targeted therapies.
Review
Biochemistry & Molecular Biology
Harry J. Gould, Dennis Paul
Summary: Conventional cancer treatment often leads to resistance and severe adverse effects. However, targeted therapies have emerged as a more effective and selective approach for treating cancer by delivering lethal treatment to specific cancer cells while limiting adverse effects.
Article
Biochemistry & Molecular Biology
Botle Precious Setlai, Rodney Hull, Meshack Bida, Chrisna Durandt, Thanyani Victor Mulaudzi, Aristotelis Chatziioannou, Zodwa Dlamini
Summary: Immune response is crucial for patient prognosis and response to cancer treatment. Tumors evade immune surveillance by altering antigen processing pathways and the tumor microenvironment. This review highlights the molecular signaling pathways involved in immune suppression and how cancer cells manipulate antigen processing to escape immune surveillance. Additionally, the review explores the potential use of these pathways in precision medicine and understanding drug resistance.
Review
Biochemistry & Molecular Biology
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
Summary: Molecular targeted therapy focusing on the HER-2 signaling pathway in gastric cancer has gained attention, with trastuzumab being the only approved drug for HER-2 positive advanced gastric cancer. Ongoing research is developing novel HER2-targeted drugs, and clinical trials are exploring various approaches to overcome resistance and improve treatment outcomes for HER2-positive gastric cancer patients.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Review
Pharmacology & Pharmacy
Vahideh Keyvani, Espanta Riahi, Meysam Yousefi, Seyed-Alireza Esmaeili, Rana Shafabakhsh, Amin Moradi Hasan-Abad, Maryam Mahjoubin-Tehran, Michael R. Hamblin, Samaneh Mollazadeh, Hamed Mirzaei
Summary: This article discusses the molecular mechanism of gynecologic cancer and the role of cancer stem cells (CSCs) in treatment, aiming to discover more specific therapeutic approaches to gynecologic cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Yagmur Sisman, Lau Kraesing Vestergaard, Douglas Nogueira Perez de Oliveira, Tim Svenstrup Poulsen, Tine Henrichsen Schnack, Claus Hogdall, Estrid Hogdall
Summary: This study analyzed the mutational profile of 128 Danish patients with high-grade serous ovarian cancer and found PARP inhibitors to be the most frequent potential targeted therapy, while indicating the relevance of investigating other targeted therapies based on mutational findings.
Article
Primary Health Care
Claire Elizabeth Powers Smith, Vinayak Prasad
Summary: Targeted cancer therapies involve attacking specific genetic biomarkers found in certain cancers, and includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. While these therapies have improved survival for some incurable cancers, only a small percentage of patients qualify for targeted oncology medications and fewer actually benefit.
AMERICAN FAMILY PHYSICIAN
(2021)
Review
Pharmacology & Pharmacy
Octavia Cadassou, Lars Petter Jordheim
Summary: More and more studies are focusing on the complex metabolic characteristics and plasticity of cancer cells. New metabolism-targeting therapeutic strategies, including classical and promising OXPHOS inhibitors (OXPHOSi), are being developed to address these specificities and vulnerabilities. OXPHOSi show limited efficiency as monotherapy but have potential in combination with conventional therapeutic strategies and other innovative approaches.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Elodie Peraudeau, Brigitte Renoux, Sheik Emambux, Pauline Poinot, Remi Chatre, Fabien Thoreau, Benjamin Riss Yaw, David Tougeron, Jonathan Clarhaut, Sebastien Papot
Summary: Combining bevacizumab (Bev) with a beta-glucuronidase-responsive albumin-binding prodrug of monomethyl auristatin E (MMAE) has shown to be an effective therapeutic strategy for colorectal cancer in mice.
MOLECULAR PHARMACEUTICS
(2023)
Review
Pharmacology & Pharmacy
Ilana Schlam, Paolo Tarantino, Stefania Morganti, Filipa Lynce, Dario Trapani, Erica L. Mayer, Ana C. Garrido-Castro, Ada Waks, Sara M. Tolaney
Summary: Breast cancer is a common and deadly disease in the US, and recent advancements in treatment for early-stage breast cancer include the use of immune checkpoint inhibitors for triple-negative breast cancer and CDK4/6 inhibitors for hormone receptor-positive disease. Additionally, adjuvant olaparib has shown significant improvement in outcomes for patients with BRCA1/2 mutations and high-risk HER2-negative breast cancer.
Review
Oncology
Samantha Gogola, Michael Rejzer, Hisham F. F. Bahmad, Ferial Alloush, Yumna Omarzai, Robert Poppiti
Summary: The standard of care therapy for early prostate cancer includes external beam radiation therapy, brachytherapy, radical prostatectomy, active surveillance, or a combination approach. Androgen deprivation therapy is considered for advanced disease. However, many patients eventually develop castration-resistant prostate cancer, leading to the development of targeted therapies, including prostate cancer stem cell-targeted therapies. In this review, the mechanisms of action of PCSC-targeted therapies are summarized and future development is discussed.
Editorial Material
Biotechnology & Applied Microbiology
Amanda R. Moore, Scott C. Rosenberg, Frank McCormick, Shiva Malek
Summary: The poster explores therapies targeting the frequently altered small GTPase, RAS, in cancer.
NATURE REVIEWS DRUG DISCOVERY
(2021)
Article
Cardiac & Cardiovascular Systems
Virginia S. Hahn, Kathleen W. Zhang, Lova Sun, Vivek Narayan, Daniel J. Lenihan, Bonnie Ky
Summary: The growing use of targeted therapies in oncology has led to significant improvements in survival rates, but also presents challenges in managing toxicities associated with long-term treatment. Overlapping signaling pathways may result in systemic toxicities, with cardiovascular toxicities being of particular concern.
CIRCULATION RESEARCH
(2021)
Review
Oncology
Maria Florencia Mercogliano, Sofia Bruni, Florencia Luciana Mauro, Roxana Schillaci
Summary: Breast cancer is a common and deadly disease, with HER2 overexpression being associated with a poor prognosis. While trastuzumab is the standard treatment, many patients do not respond to it. Other HER2-targeted therapies, such as pertuzumab, margetuximab, and T-DM1, as well as tyrosine kinase inhibitors, have been developed. Combination therapies with immune checkpoint inhibitors, CAR-T cells, CAR-NK cells, CAR-M cells, and vaccines are also being explored. This review discusses the different HER2-targeted therapies and potential combinations to overcome resistance.
Review
Biochemistry & Molecular Biology
Haiying Que, Qianmei Fu, Tianxia Lan, Xiaohe Tian, Xiawei Wei
Summary: This review discusses the complex roles of neutrophils in the tumor microenvironment and highlights the progress in neutrophil-targeted therapies in ongoing clinical trials.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
